BPC-157 Dosage: How the Literature Expresses the Numbers

How BPC-157 Doses Are Expressed in the Literature

BPC-157 dosage in the published work is almost entirely an animal, per-body-weight figure — not a human instruction. Rodent studies commonly express dose per kilogram, frequently around 10 microg/kg and 10 ng/kg, and as low as 10 pg per rat in some tendon work ^[1]. Gastric-ulcer cytoprotection was studied at 400 ng/kg and 800 ng/kg in rats ^[4]. These are model figures; they do not convert into a human dose, and this page does not provide one.

The little human dosing that exists comes from the three pilots, and it is heterogeneous: the intravenous safety pilot used 10 mg then 20 mg by infusion in two adults ^[10], and the interstitial-cystitis pilot used a single 10 mg intravesical dose during cystoscopy ^[14]. None of these establishes a validated human protocol — they are isolated pilot exposures, not a dosing schedule.

Routes Studied

The route list in the BPC-157 literature is wide, which reflects how exploratory the work has been. Intraperitoneal injection is the most common rodent route ^[1]. Intramuscular and intragastric routes were compared head-to-head in the gastric-ulcer study, with intramuscular outperforming intragastric ^[4]. Local and intra-lesional delivery appears in the tendon and wound work ^[1].

Every human route to date is a single pilot context: intravenous infusion in the safety pilot ^[10], intravesical instillation in the interstitial-cystitis pilot ^[14], and intra-articular injection in the knee-pain case series ^[6]. No route has a validated human dosing protocol attached to it.

Route matters for more than convenience here, because it is tied to the regulatory record: FDA's stated concerns about BPC-157 included potential immunogenicity for certain routes of administration ^[17]. The research record and the regulatory record both treat route as a variable, not a footnote — which is one more reason the animal route data do not collapse into a single human instruction.

Half-Life and Why It Shapes the Dose Discussion

The reported elimination half-life is under 30 min for the prototype peptide in a rat and dog PK study using intravenous and intramuscular routes ^[2]. The same study reported linear pharmacokinetics, intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, and excretion via urine and bile ^[2].

A half-life that short means blood levels fall quickly after each dose, which is why rodent protocols typically use repeated daily administration rather than a single exposure ^[1]. It also means the molecule is cleared and metabolized into small fragments well before the days-long healing outcomes appear. There is no validated human pharmacokinetic profile, so any human dosing interval would be unsupported by data.

Why Animal Per-Kilogram Figures Do Not Become a Human Dose

The most common request the BPC-157 literature cannot fill is a human dose, and the reason is structural, not coy. The bulk of the dosing data is per-kilogram in rats and dogs ^[1][2][4], and per-kilogram figures do not scale linearly to humans — interspecies differences in metabolism, surface area and clearance mean a rodent microg/kg figure has no validated human equivalent. The PK study itself reported different intramuscular bioavailability between rats and dogs — roughly 14-19% versus 45-51% ^[2] — which is a direct demonstration that even two animal species handle the molecule differently.

The three human exposures that exist were not dose-finding studies. They were a 10 mg then 20 mg intravenous safety pilot in two adults ^[10] and a single 10 mg intravesical dose in an interstitial-cystitis pilot ^[14]; the knee-pain case series did not standardize a dose at all ^[6]. None was designed to establish how much, how often, or for how long — so no human schedule can be drawn from them.

Stability, Reconstitution, and the Limits of This Page

The peptide is described as a stable gastric pentadecapeptide because it is reported to be stable in human gastric juice, which underlies the research interest in oral and peroral administration ^[4]. Despite that stability, formal human oral pharmacokinetics are not established ^[11]. Reconstitution — dissolving a lyophilized peptide in a diluent — and storage practices discussed in research handling are laboratory-context, not validated clinical protocols.

This page is a readout of how the studies expressed their doses. It is not a recommendation, a schedule, or a protocol for any person. For how those doses connect to the molecule's mechanism, see the VEGFR2 angiogenesis mechanism; for the regulatory picture around access, see the BPC-157 legal status page.